Marwan Fakih

City Of Hope National Medical Center

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

SciProfiles

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects

Research Interests

Marwan Fakih has a total of 877 co-authors. Here are the top co-authors by number of shared publications:

Chongkai Wang
City of Hope National Medical Center 1 Department of Medical Oncology and Therapeutics Research Duarte, California
35 shared publications
Neil Howard Segal
Memorial Sloan Kettering Cancer Center, New York, NY
30 shared publications
Peter P. Lee
Department of Immuno-Oncology, Beckman Research Institute, City of Hope, Duarte, USA
30 shared publications
Wells A. Messersmith
University of Colorado School of Medicine 6 Division of Medical Oncology, Department of Medicine Aurora, Colorado
30 shared publications
Jian Ye
Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, FL 32608, USA
29 shared publications
Colt A. Egelston
Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, California
28 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
C-800-01 SAP 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Statistical analysis plan to support the main manuscript.
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
C-800-01 SAP 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Statistical analysis plan to support the main manuscript.
Open Access
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
C-800-01 Protocol 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Clinical trial protocol to support the main manuscript.
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
C-800-01 Protocol 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Clinical trial protocol to support the main manuscript.
Open Access
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
(A) Best overall response, (B) response over time, and (C) DOR in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025. an = 121 patients with percent change from baseline in tumor measurement. bResponse data for this patient were corrected because of a documented database error identified after database lock; correction reflects validated source data.
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
(A) Best overall response, (B) response over time, and (C) DOR in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025. an = 121 patients with percent change from baseline in tumor measurement. bResponse data for this patient were corrected because of a documented database error identified after database lock; correction reflects validated source data.
Open Access
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
(A) PFS and (B) OS in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025.
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
(A) PFS and (B) OS in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025.
Open Access
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
(A) Best overall response, (B) response over time, and (C) DOR in patients with MSS mCRC NLM previously exposed to available late-line therapiesa who received either dose of BOT + BAL. Data cutoff: December 13, 2025. aReceived ≥1 prior regimen of regorafenib, trifluridine/tipiracil ± bevacizumab, or fruquintinib. This was an exploratory, post hoc subgroup analysis.
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
(A) Best overall response, (B) response over time, and (C) DOR in patients with MSS mCRC NLM previously exposed to available late-line therapiesa who received either dose of BOT + BAL. Data cutoff: December 13, 2025. aReceived ≥1 prior regimen of regorafenib, trifluridine/tipiracil ± bevacizumab, or fruquintinib. This was an exploratory, post hoc subgroup analysis.
Open Access
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Appendix 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplemental Appendix 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Open Access
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Demographics and baseline disease characteristics of all patients with MSS mCRC NLM (N = 123).
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Demographics and baseline disease characteristics of all patients with MSS mCRC NLM (N = 123).
Open Access
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Safety overview, including the most common treatment-related imAE and TRAE (occurred in ≥10% of patients with MSS mCRC NLM; N = 123).
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Safety overview, including the most common treatment-related imAE and TRAE (occurred in ≥10% of patients with MSS mCRC NLM; N = 123).
Open Access
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Efficacy overview in all patients with MSS mCRC NLM (N = 123).
Website
Google Scholar
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
by Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, et al.
Efficacy overview in all patients with MSS mCRC NLM (N = 123).
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Descriptive summary of serum PF-07062119 PK parameters (with 400 μg priming dose) for cycle 1.
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Descriptive summary of serum PF-07062119 PK parameters (with 400 μg priming dose) for cycle 1.

Show all